首页> Anticancer Research: International Journal of Cancer Research and Treatment> Comparison between DCF (docetaxel, cisplatin and 5-fluorouracil) and modified EOX (epirubicin, oxaliplatin and capecitabine) as palliative first-line chemotherapy for adenocarcinoma of the upper gastrointestinal tract

Comparison between DCF (docetaxel, cisplatin and 5-fluorouracil) and modified EOX (epirubicin, oxaliplatin and capecitabine) as palliative first-line chemotherapy for adenocarcinoma of the upper gastrointestinal tract

导出原文传递

翻译打印收藏纠错

第一作者： Ilhan-Mutlu,A.

作者： Ilhan-Mutlu,A. ^[1] ; Preusser,M. ^[2] ; Schoppmann,S.F. ^[3] ; Asari,R. ^[4] ; Ba-Ssalamah,A. ^[5] ; Schwameis,K. ^[6] ; Pluschnig,U. ^[7] ; Birner,P. ; Puspok,A. ; Zacherl,J. ; Hejna,M.

作者单位： Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Austria ^[1] Department of Internal Medicine i, Clinical Division of Oncology, Medical University of Vienna ^[2] Clinical Institute of Pathology, Medical University of Vienna, Vienna, Austria, Comprehensive ^[3] Department of Radiology, Division of Gastroenterology and Hepatology, Austria, Comprehensive Cancer ^[4] Department of General Surgery, Division of Gastroenterology and Hepatology, Austria, Comprehensive ^[5] Department of General Surgery, Division of Gastroenterology and Hepatology, Austria ^[6] Department of General Surgery, Division of Gastroenterology and Hepatology, Austria, Clinical ^[7]

关键词 5-fluorouracil Adenocarcinoma Capecitabine Cisplatin Docetaxel Epirubicin G-CSF Gastroesophageal cancer Oxaliplatin

发布时间 2013-12-19

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交